These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28919099)

  • 21. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids.
    Schultz HB; Wignall AD; Thomas N; Prestidge CA
    Int J Pharm; 2020 May; 582():119264. PubMed ID: 32278053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.
    Papich MG; Martinez MN
    AAPS J; 2015 Jul; 17(4):948-64. PubMed ID: 25916691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation.
    Liu Y; Li Y; Xu P; Shen Y; Tang B; Wang Q
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
    Goldwater R; Hussaini A; Bosch B; Nemeth P
    Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs.
    Li Z; Zhang W; Gao Y; Xiang R; Liu Y; Hu M; Zhou M; Liu X; Wang Y; He Z; Sun Y; Sun J
    Drug Deliv Transl Res; 2017 Feb; 7(1):100-110. PubMed ID: 27812915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
    Jinno J; Kamada N; Miyake M; Yamada K; Mukai T; Odomi M; Toguchi H; Liversidge GG; Higaki K; Kimura T
    J Control Release; 2006 Mar; 111(1-2):56-64. PubMed ID: 16410029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS).
    Christiansen ML; Holm R; Kristensen J; Kreilgaard M; Jacobsen J; Abrahamsson B; Müllertz A
    Eur J Pharm Sci; 2014 Jun; 57():164-72. PubMed ID: 24239996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs.
    Willmann S; Thelen K; Becker C; Dressman JB; Lippert J
    Eur J Pharm Biopharm; 2010 Sep; 76(1):83-94. PubMed ID: 20554023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
    Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
    Kou D; Dwaraknath S; Fischer Y; Nguyen D; Kim M; Yiu H; Patel P; Ng T; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2017 Oct; 14(10):3577-3587. PubMed ID: 28834434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of food effect on in vitro drug dissolution into biorelevant media: Contributions of solubility enhancement and relatively low colloid diffusivity.
    Jamil R; Polli JE
    Eur J Pharm Sci; 2022 Oct; 177():106274. PubMed ID: 35944878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality-by-design based development of a self-microemulsifying drug delivery system to reduce the effect of food on Nelfinavir mesylate.
    Kamboj S; Rana V
    Int J Pharm; 2016 Mar; 501(1-2):311-25. PubMed ID: 26854426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
    Taupitz T; Dressman JB; Klein S
    Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving the dissolution behaviors and bioavailability of abiraterone acetate via multicomponent crystal forms.
    Yang Z; Yang Y; Xia M; Dai W; Zhu B; Mei X
    Int J Pharm; 2022 Feb; 614():121460. PubMed ID: 35026315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.